
UroGen Pharma Ltd. (URGN)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
시가총액
$628M
수익
$90M
P/E 비율
N/A
주가순자산비율
-51.87
부채자본비율
-14.02
배당 수익률
0.00%
PEG 비율
0.22
순이익
-$127M
순이익률
-140.35%
Beta
0.398
매출 총이익
0.90%
주가매출비율
5.05
52주 최저가
$0.00
52주 최고가
$0.00
마지막 업데이트: June 30 at 19:40:56